Nattokinase for Blood Clot Prevention: Evidence and Safety Concerns

Nattokinase is derived from natto — a traditional Japanese fermented soybean dish — and has attracted growing interest as a cardiovascular supplement due to its unique fibrinolytic (clot-dissolving) activity. Unlike most supplements, which work through broad anti-inflammatory or antioxidant mechanisms, nattokinase acts enzymatically to directly degrade fibrin, the structural protein of blood clots. This makes it biologically potent — and potentially dangerous when combined with pharmaceutical anticoagulants.

What Is Nattokinase and How Was It Discovered?

Nattokinase was isolated in 1987 by Japanese researcher Dr. Hiroyuki Sumi, who was searching for a natural fibrinolytic agent. He found that natto — a traditional Japanese food with a centuries-old history — contained a serine protease enzyme with potent clot-dissolving activity. In a famous demonstration, he placed a small amount of natto on an artificial blood clot in a laboratory dish and observed that it dissolved within 18 hours — a result that would take plasminogen activators (the body's own clot-dissolving proteins) 2–3 days to accomplish in the same conditions.

This enzyme — nattokinase — is now commercially produced and standardized in units called Fibrinolytic Units (FU).

Mechanism: Fibrinolytic Activity Explained

Nattokinase operates through several complementary mechanisms:

1. Direct fibrin degradation: It cleaves fibrin directly, breaking down formed clots
2. Plasminogen activation: It activates tissue plasminogen activator (tPA) and converts plasminogen to plasmin — the body's primary clot-dissolving enzyme
3. PAI-1 reduction: It degrades plasminogen activator inhibitor-1 (PAI-1), a protein that normally prevents fibrinolysis. Elevated PAI-1 is a known cardiovascular risk factor.

This multi-target fibrinolytic profile is unique among dietary supplements. Most "natural blood thinners" work through antiplatelet mechanisms (garlic, omega-3s, ginger). Nattokinase works downstream on formed clots — a fundamentally different and more aggressive mechanism.

Clinical Evidence: What the Trials Show

The clinical evidence for nattokinase is promising but limited by trial size and design.

Fibrinolytic activity in humans: A landmark 1990 Japanese study by Sumi et al. showed that ingestion of natto by healthy volunteers increased fibrinolytic activity measurably in blood within 2 hours, with activity persisting for 2–8 hours.

NATIPBO trial (2012): A small randomized trial (n=79) showed that 2,000 FU/day of nattokinase over 6 months reduced carotid artery plaque size compared to placebo. Average plaque volume decreased by approximately 37% in the nattokinase group vs. a slight increase in the control group.

Blood pressure trial: A double-blind RCT published in Hypertension Research (2008, Kim et al.) found that 2,000 FU/day for 8 weeks reduced systolic blood pressure by 5.5 mmHg and diastolic by 2.8 mmHg in patients with pre-hypertension to stage 1 hypertension.

Thrombosis prevention: Several small Asian trials have shown reductions in whole blood viscosity and fibrinogen levels with nattokinase use.

Notably, no large-scale cardiovascular endpoint trial (like the statin trials) has been conducted for nattokinase. All available evidence comes from small, short-duration studies primarily in Asian populations.

Standard Dosage and Timing

Commercial nattokinase is standardized in Fibrinolytic Units (FU), not milligrams. The standard clinical dose used in trials is:

• 2,000 FU/day — the dose used in the majority of trials showing benefit
• Some practitioners use 4,000 FU/day for more aggressive fibrinolytic support, though this increases bleeding risk

Nattokinase has a relatively short half-life in circulation — estimated at 2–8 hours based on plasma fibrinolytic activity studies. For this reason:

• Timing matters: Evening dosing may be rational given that the majority of cardiovascular events (heart attacks, strokes) occur in the early morning, and clotting activity peaks overnight
• Consistency matters: Daily use maintains a baseline increase in fibrinolytic tone

Take nattokinase on an empty stomach where possible — food may reduce its enzymatic activity.

Critical Warning: This Is Not a Replacement for Anticoagulants

This is the most important section of this article.

Nattokinase is categorically not a replacement for prescribed anticoagulant or antiplatelet therapy. For patients prescribed:

• Warfarin (Coumadin) — clot prevention in atrial fibrillation, mechanical heart valves, DVT/PE
• Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa) — the NOAC/DOAC class
• Aspirin — antiplatelet therapy post-heart attack or stroke
• Clopidogrel (Plavix) — antiplatelet therapy

...nattokinase use without physician knowledge and monitoring is dangerous. Combining nattokinase with anticoagulants creates additive bleeding risk through complementary mechanisms. The result can be serious or fatal hemorrhage — particularly intracranial bleeding.

Do not use nattokinase if you:

• Take any anticoagulant or antiplatelet medication
• Have a bleeding disorder or hemophilia
• Are scheduled for surgery within 2 weeks
• Have a history of hemorrhagic stroke
• Are pregnant (risk of bleeding complications)

Who Might Nattokinase Actually Help?

The profile of potential benefit — given current evidence and the absence of large endpoint trials — is most plausible for:

• Healthy adults with elevated fibrinogen (a cardiovascular risk marker) not yet on anticoagulant therapy
• People with elevated blood viscosity or diagnosed hypercoagulable states, under physician monitoring
• Individuals with early-stage carotid plaque who are not on anticoagulants and want adjunctive support
• Those concerned about cardiovascular prevention who are not candidates for aspirin and want a gentler fibrinolytic approach

For any patient with established atrial fibrillation, mechanical heart valves, history of DVT/PE, or established thrombophilia — pharmaceutical anticoagulation is mandatory and cannot be safely replaced by nattokinase.

Drug Interaction Summary

| Drug Category | Interaction | Risk Level | |---------------|-------------|------------| | Warfarin | Additive anticoagulation | HIGH — do not combine without medical oversight | | NOACs (Eliquis, Xarelto) | Additive bleeding risk | HIGH | | Aspirin | Additive antiplatelet/fibrinolytic | MODERATE-HIGH | | NSAIDs | Additive GI bleeding risk | MODERATE | | Omega-3 (high dose) | Additive antiplatelet | LOW-MODERATE | | Ginkgo biloba | Additive antiplatelet | LOW-MODERATE |

The Bottom Line

Nattokinase is a genuine fibrinolytic enzyme with a unique mechanism — direct fibrin degradation — and promising preliminary evidence for blood pressure reduction, fibrinogen lowering, and possible carotid plaque regression at 2,000 FU/day. However, its potent clot-dissolving activity makes it dangerous in combination with warfarin, aspirin, and other anticoagulants. It is not a replacement for medical anticoagulation in any established thrombotic condition. For healthy adults without anticoagulant prescriptions who want to support cardiovascular health with a fibrinolytic supplement, nattokinase is the most evidence-supported option — but physician disclosure is strongly recommended.

---

Build a cardiovascular supplement stack based on your actual biomarkers and risk factors, not guesswork. Use Optimize free.

Related Articles

• Nattokinase for Cardiovascular Health: Evidence and Dosage